J Thorac Cardiovasc Surg 2005;129:25-32
© 2005 The American Association for Thoracic Surgery
Cardiopulmonary Support and Physiology
a The Cardiac Surgical Research Unit, Department of Cardiothoracic Surgery, Alfred Hospital, the Baker Heart Research Institute (Wynn Domain), and the Department of Surgery, Monash University, Melbourne, Australia
b Department of Epidemiology and Preventative Medicine, Monash University, Melbourne, Australia
c Department of Biochemistry and Molecular Biology, Monash University, Melbourne, Australia
Received for publication September 3, 2003; revisions received March 15, 2004; accepted for publication March 25, 2004.
* Address for reprints: Salvatore Pepe, PhD, Baker Heart Research Institute, PO Box 6492, St Kilda Road Central, Melbourne VIC 8008, Australia
OBJECTIVES: Previous clinical trials suggest that coenzyme Q10 might afford myocardial protection during cardiac surgery. We sought to measure the effect of coenzyme Q10 therapy on coenzyme Q10 levels in serum, atrial trabeculae, and mitochondria; to assess the effect of coenzyme Q10 on mitochondrial function; to test the effect of coenzyme Q10 in protecting cardiac myocardium against a standard hypoxia-reoxygentation stress in vitro; and to determine whether coenzyme Q10 therapy improves recovery of the heart after cardiac surgery.
METHODS: Patients undergoing elective cardiac surgery were randomized to receive oral coenzyme Q10 (300 mg/d) or placebo for 2 weeks preoperatively. Pectinate trabeculae from right atrial appendages were excised, and mitochondria were isolated and studied. Trabeculae were subjected to 30 minutes of hypoxia, and contractile recovery was measured. Postoperative cardiac function and troponin I release were assessed.
RESULTS: Patients receiving coenzyme Q10 (n = 62) had increased coenzyme Q10 levels in serum (P = .001), atrial trabeculae (P = .0001), and isolated mitochondria (P = .0002) compared with levels seen in patients receiving placebo (n = 59). Mitochondrial respiration (adenosine diphosphate/oxygen ratio) was more efficient (P = .012), and mitochondrial malondialdehyde content was lower (P = .002) with coenzyme Q10 than with placebo. After 30 minutes of hypoxia in vitro, pectinate trabeculae isolated from patients receiving coenzyme Q10 exhibited a greater recovery of developed force compared with those in patients receiving placebo (46.3% ± 4.3% vs 64.0% ± 2.9%, P = .001). There was no between-treatment difference in preoperative or postoperative hemodynamics or in release of troponin I.
CONCLUSIONS: Preoperative oral coenzyme Q10 therapy in patients undergoing cardiac surgery increases myocardial and cardiac mitochondrial coenzyme Q10 levels, improves mitochondrial efficiency, and increases myocardial tolerance to in vitro hypoxia-reoxygenation stress.
This article has been cited by other articles:
M. Gendelman and Z. Roth
Incorporation of Coenzyme Q10 into Bovine Oocytes Improves Mitochondrial Features and Alleviates the Effects of Summer Thermal Stress on Developmental Competence
Biol Reprod, November 16, 2012; 87(5): 118 - 118.
[Abstract] [Full Text] [PDF]
L. Tiano, R. Belardinelli, P. Carnevali, F. Principi, G. Seddaiu, and G. P. Littarru
Effect of coenzyme Q10 administration on endothelial function and extracellular superoxide dismutase in patients with ischaemic heart disease: a double-blind, randomized controlled study
Eur. Heart J., September 2, 2007; 28(18): 2249 - 2255.
[Abstract] [Full Text] [PDF]
|HOME||HELP||FEEDBACK||SUBSCRIPTIONS||ARCHIVE||SEARCH||TABLE OF CONTENTS|
|ANN THORAC SURG||ASIAN CARDIOVASC THORAC ANN||EUR J CARDIOTHORAC SURG|
|J THORAC CARDIOVASC SURG||ICVTS||ALL CTSNet JOURNALS|